

Catalog# BP- 50576

Casirivimab Biosimilar (SARS-CoV-2 Spike Monoclonal Antibody)

Casirivimab is a human monoclonal antibody directed against the spike protein of SARS-CoV-2. Casirivimab is a human monoclonal antibody (IgG1κ isotype). Casirivimab biosimilar uses the same protein sequences as the therapeutic antibody casirivimab. Casirivimab/imdevimab is a combination medicine used for the treatment and prevention of COVID-19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. Casirivimab and imdevimab bind distinct epitopes on the RBD with dissociation constants KD of 46 and 47 pM, respectively. Please contact us if you are interested in the anti-SARS-CoV-2 spike monoclonal antibody imdevimab biosimilar.

Product Details	
CAS No.	2415933-42-3
Species Reactivity	Human
Source	Casirivimab biosimilar CHO cells
Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Clone	Casirivimab Biosimilar
Conjugate	Unconjugated
Immunogen	Human spike protein of SARS-CoV-2
Purity	>95%
Molecular Weight	145.24 kDa
Protein Concentration	1 mg/ml
Formulation	0.2 μM filtered PBS solution, pH 7.4
Storage conditions	4°C for short time, -20°C or -80°C for long time.